“…Another study showed that miR‐4443 promoted Epi resistance in non‐small‐cell lung cancer by downregulating inositol polyphosphate‐4‐phosphatase Type I A and activating Janus kinase 2/signal transducer and activator of transcription 3 pathway (W. Zhang et al, 2018). However, miR‐4443 showed a beneficial effect in ovarian cancer, glioblastoma, osteosarcoma, hepatocellular carcinoma, and colon cancer (Ebrahimi & Reiisi, 2019; Gao et al, 2019; Gong, Wang, Liu, Hu, & Zheng, 2018; Meerson & Yehuda, 2016; C. Zhou et al, 2018). Taking together, miR‐4443 may play different roles in different cancers.…”